Fight over Supreme Court dialysis ruling puts kidney patients at risk

AdobeAssoonassheheardtheSupremeCourtdecision,LaVarneBurtonbegantoworry.AsCEOofthenonprofitAmericanKi AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul




hotspot

author：entertainment    Page View：4556
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： What’s missing from the debate over nursing home staff minimums
Next article： United colonoscopy coverage change 'may cost lives,' doctors say